Abstracts Archive - Page 1384 of 2607 - ACR Meeting Abstracts

Abstract Number: 2967 • 2018 ACR/ARHP Annual Meeting
Potent Bifunctional Inhibitors of Xanthine Oxidase and URAT1 Block Fructose-Induced Inflammation Via Increase in AMP Kinase Activity
Laura Gabriela Sánchez Lozada¹, Fernando E. García-Arroyo², J. Gabriel Juárez-Rojas³, Guillermo Gonzaga² and Raymond P. Warrell Jr.⁴, ¹Nephrology, INC Ignacio Chavez, Mexico City, Mexico, ²INC Ignacio Chavez, Mexico City, Mexico, ³INC Ignacio Chavez, Mexoci City, Mexico, ⁴Relburn-Metabolomics, Inc., Westfield, NJ
Background/Purpose: Dietary fructose promotes an increase in uric acid (UA) that may lead to gout. UA itself promotes lipogenesis and inflammation in both gout as…
Abstract Number: 2968 • 2018 ACR/ARHP Annual Meeting
Role of Choline in Gouty Inflammation
Elsa Sanchez-Lopez¹, Zhenyu Zhong¹, Alex Stubelius², Shannon R Sweeney³, Ru Liu-Bryan^4,5, Juan Carlos Lacal⁶, Stefano Tiziani^3,7,8, Robert Terkeltaub^4,9, Monica Guma⁹ and Michael Karin¹, ¹Department of Pharmacology, School of Medicine. UCSD., La Jolla, CA, ²Division of Rheumatology, Allergy and Immunology. UCSD., La Jolla, CA, ³Department of Nutritional Sciences. The University of Texas at Austin., Austin, TX, ⁴VA San Diego Healthcare System, San Diego, CA, ⁵Medicine-Rheumatology, Division of Rheumatology, Allergy and Immunology. UCSD., La Jolla, CA, ⁶Translational Oncology. Department of Oncology, Hospital Universitario Fuenlabrada, Madrid, Spain, ⁷Department of Molecular Biosciences, College of Natural Sciences. The University of Texas at Austin., Austin, TX, ⁸Department of Pediatrics, Dell Medical School. The University of Texas at Austin., Austin, TX, ⁹Medicine, Division of Rheumatology, Allergy and Immunology. UCSD., La Jolla, CA
Background/Purpose: Gout is characterized by deposition of monosodium urate (MSU) crystals in articular joints, where they activate macrophages inducing NLRP3 inflammasome activation and bioactive IL-1β…
Abstract Number: 2969 • 2018 ACR/ARHP Annual Meeting
Allopurinol Dose Escalation Slows Progression of CT Bone Erosion in People with Gout: Imaging Sub-Study of a Randomized Control Trial
Nicola Dalbeth¹, Karen Billington², Anthony Doyle¹, Christopher Frampton³, Paul Tan¹, Jordyn Allan¹, Jill Drake⁴, Anne Horne⁵ and Lisa K. Stamp³, ¹University of Auckland, Auckland, New Zealand, ²Auckland District Health Board, Auckland, New Zealand, ³University of Otago, Christchurch, New Zealand, ⁴University of Otago, Christchurch, Christchurch, New Zealand, ⁵Department of Medicine, University of Auckland, Auckland, New Zealand
Background/Purpose: Bone erosion is a frequent complication of severe gout. Computed tomography (CT) is considered the gold standard for measurement of bone erosion. CT studies…
Abstract Number: 2970 • 2018 ACR/ARHP Annual Meeting
In Idiopathic Retroperitoneal Fibrosis, Persistent FDG PET Uptake Helps Identifying Patients at Risk for Relapse
Gabriel Morin¹, Arthur Mageau¹, Khadija Benali¹, Eve Piekarski¹, Remi Bertinchamp¹, Quentin Raimbourg¹, Jean Francois Alexandra², Antoine Dossier¹, Tiphaine Goulenok¹, Damien van Gysel¹, Thomas Papo¹ and Karim Sacre², ¹Université Paris-Diderot, Paris, France, ²Bichat Hospital, Paris Diderot University, Paris, France
Background/Purpose: Idiopathic retroperitoneal fibrosis (IRF) is a rare disease characterized by abdominal periaortic fibro-inflammatory tissue. The aim of this study was to evaluate the prognostic…
Abstract Number: 2971 • 2018 ACR/ARHP Annual Meeting
Rituximab Associated Hypogammaglobulinemia in Autoimmune Disease: Long Term Outcomes
Joanna Tieu^1,2, Seerapani Gopaluni^3,4, Rona Smith¹ and David Jayne¹, ¹Department of Medicine, University of Cambridge, Cambridge, United Kingdom, ²Department of Medicine, University of Adelaide, Adelaide, Australia, ³Medicine, University of Cambridge, Cambridge, United Kingdom, ⁴Vasculitis and Lupus, Addenbrooke’s Hospital, Cambridge, United Kingdom
Background/Purpose: Despite a low incidence of hypogammaglobulinemia (HG) in clinical trials using rituximab (RTX), HG occurs in follow-up of patients with autoimmune disease. Immunoglobulin replacement…
Abstract Number: 2972 • 2018 ACR/ARHP Annual Meeting
Multicentric Reticulohistiocytosis (1980-2017): A Rare Disease, Commonly Associated with Malignancy and Autoimmunity
Avneek Singh Sandhu¹, Cynthia S. Crowson², David Wetter³, Gavin McKenzie⁴ and Ashima Makol¹, ¹Rheumatology, Mayo Clinic, Rochester, MN, ²Health Sciences Research, Mayo Clinic College of Medicine and Science, Rochester, MN, ³Dermatology, Mayo Clinic, Rochester, MN, ⁴Radiology, Mayo Clinic, Rochester, MN
Background/Purpose: Multicentric reticulohistiocytosis (MRH) is a systemic disease characterized by papulo-nodular skin eruptions and progressive, deforming arthritis. We aimed to examine the clinical correlates and…
Abstract Number: 2973 • 2018 ACR/ARHP Annual Meeting
Clinical Features and Pulmonary Function Test Findings Associated with Large Airway Disease in Relapsing Polychondritis
Marcela A. Ferrada¹, Arlene Sirajuddin², En lin Goh³, Kaitlin Quinn⁴, Katherine B. Gribbons⁵, John Hansen-Falschen⁶, Nitin Seam², Robert Colbert⁷, Keith A. Sikora⁸, Wendy Goodspeed⁹, Angeline Thomas², H. Jeffrey Kim¹⁰, Allen Clint², Marcus Chen¹¹, James D. Katz¹² and Peter C. Grayson¹³, ¹Critical Care, National Institutes of Health, Bethesda, MD, ²National Institutes of Health, Bethesda, MD, ³Faculty of Medicine Imperial College, London, United Kingdom, ⁴Systemic Autoimmunity Branch, NIAMS, Bethesda, MD, ⁵Systemic Autoimmunity Branch, National Institute of Arthritis and Skin and Musculoskeletal Disease, Bethesda, MD, ⁶Medicine, University of Pennsylvania, Philadelphia, PA, ⁷National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, MD, ⁸Pediatric Translational Research Branch, National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, MD, ⁹Office of the Clinical Director, NIAMS/NIH, Bethesda, MD, ¹⁰National Institute of Deafness and Other Communication Disorders, Bethesda, MD, ¹¹NHLBI, National Institutes of Health, Bethesda, MD, ¹²National Institute of Arthritis, Musculoskeletal and Skin Disease (NIAMS), Bethesda, MD, ¹³National Institute of Arthritis, Musculoskeletal and Skin Disease, National Institutes of Health, Bethesda, MD
Clinical Features and Pulmonary Function Test Findings Associated with Large Airway Disease in Relapsing Polychondritis Background/Purpose: Relapsing polychondritis (RP) is a systemic disease that can lead…
Abstract Number: 2974 • 2018 ACR/ARHP Annual Meeting
Long-Term Survival in Lung Transplantation for Interstitial Lung Disease Due to Rheumatic Systemic Diseases. Study of 26 Cases of a Single Center
Diana Prieto Peña¹, Amaya Martinez Meñaca², Monica Calderón Goercke¹, José Luis Martín-Varillas³, Belén Atienza-Mateo³, Victor Manuel Mora Cuesta², Sonia Fernandez Rozas⁴, David Iturbe Fernandez⁴, Carmen González-Vela⁵, Jose Manuel Cifrian Martinez⁴, Miguel Angel González-Gay⁶ and Ricardo Blanco³, ¹Rheumatology, Rheumatology. Hospital Universitario Marqués de Valdecilla. IDIVAL. Santander. Universidad de Cantabria. Spain, Santander, Spain, ²Neumology, Hospital Universitario Marqués de Valdecilla. IDIVAL. Santander. Universidad de Cantabria. Spain, SANTANDER, Spain, ³Rheumatology, Hospital Universitario Marqués de Valdecilla. IDIVAL. Santander. Universidad de Cantabria. Spain, Santander, Spain, ⁴Neumology, Hospital Universitario Marqués de Valdecilla. IDIVAL. Santander. Universidad de Cantabria. Spain, Santander, Spain, ⁵Pathology, Hospital Universitario Marqués de Valdecilla. IDIVAL. Santander. Universidad de Cantabria. Spain, Santander, Spain, ⁶School of Medicine, University of Cantabria, Santander, Spain, Santander, Spain
Background/Purpose: Interstitial lung disease (ILD) is one of the most serious complications associated with rheumatic systemic diseases. Patients with ILD have increased mortality and limited…
Abstract Number: 2975 • 2018 ACR/ARHP Annual Meeting
Anti-Il-1 Therapies in Patients with Familial Mediterranean Fever Related AA-Amyloidosis
Bilgesu Ergezen¹, Serdal Ugurlu², Oguzhan Selvi³, Bugra Han Egeli⁴ and Huri Ozdogan³, ¹Division of Rheumatology, Department of Internal Medicine, Cerrahpasa Medical Faculty, University of Istanbul, Istanbul, Turkey, ²Istanbul University, Cerrahpasa Medical Faculty, Department of Internal Medicine, Division of Rheumatology, Istanbul, Turkey, ³Division of Rheumatology, Department of Internal Medicine, Cerrahpasa Medical Faculty, University of Istanbul, Istanbul, Turkey, ⁴Cerrahpasa Medical Faculty, University of Istanbul, Istanbul, Turkey
Background/Purpose: The most devastating complication of Familial Mediterranean Fever is secondary AA amyloidosis and is still a problem in many cases. Efforts have been paid…
Abstract Number: 2976 • 2018 ACR/ARHP Annual Meeting
Immune Checkpoint Inhibitor-Associated Myositis: A Characteristic Phenotype with a Poor Outcome Related to Concomitant Myocarditis
Celine Anquetil^1,2, Joe-Elie Salem^3,4, Benedicte Lebrun-Vignes⁵, Douglas B Johnson⁶, Andrew Mammen^7,8, Werner Stenzel⁹, Sarah Leonard-louis¹⁰, Olivier Benveniste^11,12, Javid J Moslehi³ and Yves Allenbach^2,13, ¹Internal Medicine and Clinical Immunlogy, Assistance Public - Hopitaux de Paris, Pitié-Salpêtrière University Hospital, PARIS, France, ²CDR en myologie UMR974,, Institut National de la Santé et de la Recherche Médicale, Association Institut de Myologie, PARIS, France, ³Division of Cardiovascular Medicine and Cardio-Oncology Program, Department of Medicine, Vanderbilt University Medical Center, Nasheville, TN, ⁴Department of Pharmacology, Regional Center of Pharmacovigilance, INSERM, CIC-1421, Paris, France, ⁵Department of Pharmacology, Regional Center of Pharmacovigilance, INSERM, CIC-1421, PARIS, France, ⁶Division of Oncology, Department of Medicine, Vanderbilt University Medical Center, Nasheville, TN, ⁷National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, MD, ⁸Neurology, Johns Hopkins University School of Medicine, Baltimore, MD, ⁹Charité - Universitätsmedizin, Department of Neuropathology, Berlin, Germany, Berlin, Germany, ¹⁰Département de Neuropathologie, Centre de Référence des Maladies Neuro-Musculaires Paris Est, Assistance Publique – Hôpitaux de Paris (AP-HP), Hôpital Universitaire Pitié-Salpêtrière, Paris, France, ¹¹Department of Internal Medicine and Clinical Immunology and Inflammation-Immunopathology-Biotherapy Department (I2B), Pitié-Salpêtrière University Hospital, Assistance Publique-Hôpitaux de Paris, East Paris Neuromuscular Diseases Reference Center, Paris, France, ¹²Centre de Recherche en Myologie, UMRS974, Institut National de la Santé et de la Recherche Médicale, Association Institut de Myologie, Paris, France, ¹³Internal Medicine and Clinical Immunology, Sorbonne University - Assistance Public - Hopitaux de Paris, Pitié-Salpêtrière University Hospital, Paris, France
Background/Purpose: Immune checkpoint inhibitors (ICI) are a major breakthrough in cancer treatment providing frequent durable responses and improving overall survival. Blocking immune checkpoints (Programmed cell…
Abstract Number: 2977 • 2018 ACR/ARHP Annual Meeting
Lenabasum, a Cannabinoid Type 2 Receptor Agonist, Reduces T-Cell Population and Downregulates Type 1 and 2 Interferon Activities in Lesional Dermatomyositis Skin
Nithin Reddy^1,2, Majid Zeidi^1,2, Barbara White³ and Victoria P. Werth^1,2, ¹University of Pennsylvania, Philadelphia, PA, ²Philadelphia Veterans Affairs Medical Center, Philadelphia, PA, ³Corbus Pharmaceuticals, Inc., Norwood, MA
Background/Purpose: Lenabasum is a synthetic, non-immunosuppressive, selective cannabinoid receptor type 2 (CB2) agonist that activates resolution of innate immune responses. CB2 is a G-protein coupled…
Abstract Number: 2978 • 2018 ACR/ARHP Annual Meeting
Performance of the 2017 European League Against Rheumatism / American College of Rheumatology (EULAR/ACR) Classification Criteria for Adult Idiopathic Inflammatory Myopathies (IIM) in an Australian Cohort
Queenie Luu¹, Jessica Day^2,3, Alix Hall⁴, Vidya Limaye^2,5 and Gabor Major^6,7, ¹Rheumatology, Bone and Joint Institute, John Hunter Hospital, New Lambton Heights, Australia, ²Rheumatology, The Royal Adelaide Hospital, Adelaide, Australia, ³School of Pharmacy and Medical Sciences, University of South Australia, Adelaide, Australia, ⁴Hunter Medical Research Institute, New Lambton Heights, Australia, ⁵Discipline of Medicine, University of Adelaide, South Australia, Adelaide, Australia, ⁶Rheumatology, Bone and Joint Institute, John Hunter Hospital, Newcastle, Australia, ⁷University of Newcastle, Newcastle, Australia, Newcastle, Australia
Background/Purpose: EULAR/ACR recently approved classification criteria for idiopathic inflammatory myopathies (IIM) with 93% sensitivity and 88% specificity. An acknowledged limitation of the study is the…
Abstract Number: 2979 • 2018 ACR/ARHP Annual Meeting
Innovative Approaches for the Assessment of Interstitial Lung Disease in Idiopathic Inflammatory Myopathies: Ultrasound Evaluation of Pleural Irregularities and Semiquantitative and Quantitative Analysis of Lung CT
Simone Barsotti^1,2, Chiara Romei³, Elisa Cioffi⁴, Claudia Roncella⁵, Elisabetta Perrone³, Alessandra Tripoli¹, Marta Mosca¹, Fabio Falaschi³ and Rossella Neri⁶, ¹Rheumatology Unit, University of Pisa, Pisa, Italy, ²Department of Medical Biotechnologies, University of Siena, Siena, Italy, ³Pisa University Hospital, II Radiology Unit, Pisa, Italy, ⁴Rheumatology Unit, Rheumatology Unit, University of Pisa, Pisa, Italy, ⁵Pisa University Hospital, I Radiology Unit, Pisa, Italy, ⁶Rheumatology Unit, University of Pisa, PISA, Italy
Background/Purpose: Interstitial Lung Disease (ILD) in patients with Idiopathic Inflammatory Myopathies (IIM) is associated to high mortality and morbidity. The study of pleural irregularities (PI)…
Abstract Number: 2980 • 2018 ACR/ARHP Annual Meeting
Calcineurin Inhibitor for the Treatment of Myositis-Associated Interstitial Lung Disease: Comparison between Cyclosporine and Tacrolimus
Takahisa Gono¹, Kenichi Masui², Naoshi Nishina³, Shinji Sato⁴ and Masataka Kuwana¹, ¹Department of Allergy and Rheumatology, Nippon Medical School Graduate School of Medicine, Tokyo, Japan, ²Department of Anesthesiology, Show University Hospital, Tokyo, Japan, ³Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine, Tokyo, Japan, ⁴Division of Rheumatology, Department of Internal Medicine, Tokai University School of Medicine, Isehara, Japan
Background/Purpose: Treatment options for myositis-associated interstitial lung disease (ILD) include corticosteroids (CS) in combination with or without cyclophosphamide (CY), calcineurin inhibitors (CNIs) such as cyclosporine…
Abstract Number: 2981 • 2018 ACR/ARHP Annual Meeting
Mitochondrial Extrusion and Autoimmunity in Juvenile Dermatomyositis
Christian Lood¹, Bhargavi Duvvuri², Richard Moore², Gabrielle A. Morgan³, Marisa Klein-Gitelman⁴, Megan L. Curran⁵ and Lauren M. Pachman⁶, ¹Department of Medicine, Division of Rheumatology, University of Washington, Seattle, WA, ²Division of Rheumatology, University of Washington, Seattle, WA, ³Cure JM Program of Excellence in Myositis Research, Stanley Manne Children’s Research Institute, affiliated with Ann & Robert H. Lurie Children’s Hospital of Chicago, Chicago, IL, ⁴Ann and Robert H. Lurie Children's Hospital of Chicago, Chicago, IL, ⁵Section of Rheumatology, Children's Hospital of Colorado, Denver, CO, ⁶Cure JM Program of Excellence in Juvenile Myositis Research, Stanley Manne Children’s Research Institute, affiliated with Ann & Robert H. Lurie Children’s Hospital of Chicago, Chicago, IL
Background/Purpose: We recently made the fundamental observation that mitochondrial extrusion is instrumental in mediating inflammation, autoimmunity and organ damage in lupus. Mitochondrial stress and mitochondrial…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].